Physician profile
Benjamin Cameron
NPI 1205248424
$3,103.60
in general payments reported to CMS, 2019-2025
31 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $11.96 · 2022: $263 · 2023: $607 · 2024: $773 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.74 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $383.02 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $273.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $242.17 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $236.74 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company Ltd. | $145.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.61 | 2019-2024 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $138.21 | 2023-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $126.02 | 2023-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $115.34 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $107.19 | 2023-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $94.58 | 2024-2025 | Symbravo, Auvelity |
| Kowa Pharmaceuticals America, INC. | $91.92 | 2023 | Seglentis, Livalo |
| Boston Scientific Corporation | $61.39 | 2019-2025 | Watchman Access System, Watchman Flx |
| Merck Sharp & Dohme LLC | $37.79 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33.76 | 2024-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.37 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $29.14 | 2023-2025 | Contrave, Onzetra Xsail |
| Ge Healthcare | $27.58 | 2019 | |
| Corium, LLC | $26.98 | 2025 | Azstarys |
| Phathom Pharmaceuticals, INC. | $25.34 | 2024-2025 | Voquezna |
| Cequr Corporation | $21.59 | 2025 | Cequr Simplicity |
| Abiomed | $20.71 | 2025 | |
| Abbott Laboratories | $20.62 | 2025 | Freestyle Libre 3 |
| Halozyme INC | $19.95 | 2023 | |
| Astellas Pharma US INC | $15.68 | 2023 | Veozah |
| Linus Health, INC. | $15.29 | 2023 | |
| Amarin Pharma, INC. | $15.21 | 2022 | |
| Exact Sciences Corporation | $14.02 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $13.82 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $13.53 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.